In recent years, interventional treatment mainly developed around coronary arteries has been applied to new fields such as brain and peripheral blood vessels. In such conditions, Kaneka has a comprehensive product lineup in the field of peripheral blood vessels and has targeted strengthening its sales network for further sales expansion. At the same time, Terumo has sought further enhancement of its product lineup to expand and reinforce its interventional systems business.
The conclusion of this agreement is the result of the matched needs of Kaneka for sales network expansion and Terumo for product lineup enhancement.
Terumo will further strengthen its product lineup with the addition of PTA balloon catheters in the field of interventional treatment. We shall continue to contribute to healthcare service as a "total supplier of interventional treatment" by proactively integrating technologies of other companies into our company through cooperation and other approaches.
1. Terumo Corporation 1) Main business: Manufacture and sales of medical products, equipment, and pharmaceutical products 2) Head office: 44-1, 2-chome, Hatagaya, Shibuya-ku, Tokyo 3) Representative: Yutaro Shintaku, Representative Director & President 4) Capita stockl: 38.7 billion yen (as of March 31, 2010) 5) Sales: 316 billion yen (consolidated, fiscal year ending March 2010) 2. Kaneka Corporation 1) Main business: Manufacture and sales of chemicals, functional plastics, expandable plastics and products, foodstuffs products, life science products, electronic products and synthetic fibers 2) Head office: 3-2-4, Nakanoshima, Kita-ku, Osaka 3) Representative: Kimikazu Sugawara, Representative Director & President 4) Capital stock: 33,046 million yen (as of March 31, 2010) 5) Sales: 412.5 billion yen (consolidated, fiscal year ending March 2010)3. Kaneka Medix Corporation 1) Main business: Manufacture, importation and sales of medical products and equipment 2) Head office: 3-2-4, Nakanoshima, Kita-ku, Osaka 3) Representative: Akihiko Iguchi, Representative Director & President 4) Capital stock: 450 million yen (100% held by Kaneka Corporation)
The impact of this on our business results is limited, and there is no revision in the financial forecast for the current fiscal year. (Notice) Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.The market share information in this booklet is partly derived from our own independent research.